COSMOS Pharmaceutical (3349) Q4 2024 earnings summary

Executive summary

• Net sales rose 16.6% year-over-year to ¥964,989 million, with operating profit up 4.6% and profit attributable to owners of parent up 2.8%.

• 139 new stores were opened, bringing the total to 1,490, with a focus on price competitiveness amid rising consumer prices.

Financial highlights

• Operating profit reached ¥31,501 million (up 4.6% year-over-year), ordinary profit ¥34,299 million (up 3.7%), and net income ¥24,454 million (up 2.8%).

• Gross margin was ¥188,305 million, and basic EPS was ¥617.22.

• Total assets increased 13.2% to ¥476,546 million; net assets rose 9.7% to ¥231,442 million.

Outlook and guidance

• Fiscal year ending May 31, 2025 forecast: net sales ¥1,037,000 million (+7.5%), operating profit ¥31,600 million (+0.3%), net income ¥24,500 million (+0.2%).

• Continued focus on low prices and aggressive store openings, especially in Kanto, Chubu, and Kansai.